CoChat
Sign Up
Cited by 15Advanced Drug Delivery SystemsNanoparticle-Based Drug DeliveryReproductive tract infections research

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Design and evaluation of antibacterials crosslinked chitosan nanoparticle as a novel carrier for the delivery of metronidazole to treat bacterial vaginosis

Nayak, Reena, Halder, Jitu, Rajwar, Tushar Kanti, Pradhan, Deepak, Dash, Priyanka, Das, Chandan, Rai, Vineet Kumar, Kar, Biswakanth, Ghosh, Goutam, Rath, Goutam·2024·Microbial Pathogenesis
DOI 10.1016/j.micpath.2023.106494
Open this paper in CoChat — free account

Abstract

Bacterial vaginosis (BV) is a recurring, chronic infection that is difficult to treat due to the limited bioavailability of antimicrobials within vaginal epithelial cells. Vaginal administration, because of lower dosing and systemic exposure offers a viable option for treating vaginal infections. In this study, Metronidazole-loaded chitosan nanoparticles were synthesised employing borax (BX) or tannic acid (TA) as an antimicrobial crosslinking agent for treating BV. The prepared NPs were characterized for various physical, physicochemical, pharmaceutical, thermal and antibacterial properties. Morphological investigation revealed that nanoparticles prepared from 0.5 % w/v chitosan, 1.2 % w/v BX, and 0.4 % w/v metronidazole (MTZ) were non-spherical, with particle sizes of 377.4 ± 37.3 nm and a zeta potential of 34 ± 2.1 mV. The optimised formulation has MIC values of 24 ± 0.5 and 59 ± 0.5 μg/mL, against Escherichia coli (E.coli) and Candida albicans (C.albicans) respectively. The results of DSC and XRD demonstrated no change in the physical state of the drug in the finished formulation. Under simulated vaginal fluid, the optimised formulation demonstrates a cumulative drug release of about 90 % within 6h. The prepared borax crosslinked NPs exhibit anti-fungal activities by inhibiting ergosterol synthesis. The in-vivo antibacterial data indicated a comparable reduction in bacterial count compared to the marketed formulation in female Swiss albino mice treated with optimised nanoparticles. According to histopathological findings, the prepared nanoparticle was safe for vaginal use. Based on the experimental findings, it was concluded that MBCSNPs, due to their good physiochemical and antimicrobial properties, could serve as a potential topical alternative for treating BV and reducing fungal infection.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.micpath.2023.106494

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. Chávez de Paz, 2011, Antimicrobial effect of chitosan nanoparticles on, Streptococcus mutans biofilms, 77, 3892
  2. Dinesh, 2013, Study of antifungal activity of boric acid on vaginal pathogens, Int. J. Adv. Biotechnol., 4, 319

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Nayak, R., Halder, J., Rajwar, T. K., Pradhan, D., Dash, P., Das, C., Rai, V. K., Kar, B., Ghosh, G., & Rath, G.
Affiliations
Siksha O Anusandhan University (IN)
Corresponding author
Rath, Goutam
ORCID
Venue
Microbial Pathogenesis
Publisher
Elsevier BV
Published
2024-01
Volume
186
Pages
106494
ISSN
0882-4010 (ISSN-L)
DOI
10.1016/j.micpath.2023.106494
OpenAlex
W4389410287
Cited by
15
References
49
Citations by year
2026: 2 · 2025: 7 · 2024: 6
FWCI
1.64
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Microbial Pathogenesis (publishedVersion)
  • PubMed (publishedVersion)
Funders
Department of Biotechnology, Ministry of Science and Technology, India (BT/INF/22/SP45078/2022)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
bacterial vaginosis, chitosan nanoparticles, metronidazole, borax crosslinking, tannic acid crosslinking, vaginal drug delivery, antibacterial nanoparticles, antifungal activity, Candida albicans, Escherichia coli, nanoparticle safety
MeSH terms
Animals, Anti-Bacterial Agents, Borates, Drug Carriers, Female, Humans, Metronidazole, Particle Size, Vaginosis, Bacterial, Chitosan, Mice, Nanoparticles, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review